With a tiny change to the rules, the Food and Drug Administration made it a bit harder for Martin Shkreli and his ilk to make a killing by jacking up the prices of off-patent drugs.

The regulatory tweak now allows a “priority” or expedited review process for any generic drug that would compete with an off-patent drug that is only made by one company—the kinds of drugs that have seen skyrocketing price tags of late. The faster review process could cut the window for a pharmaceutical company to have a monopoly over the drug from years to months, sharply cutting profits from potential price gouging.

In an e-mail to Bloomberg, FDA spokesperson Sandy Walsh wrote that the agency expects as many as 125 generic drug applications will now be fast-tracked due to the change. The agency previously expedited reviews of generics that would compete with newly off-patent brand name drugs.

The FDA’s revision comes amid nationwide outrage over the price-gouging ways of the pharmaceutical industry, with several companies in particular standing out, including Valeant Pharmaceuticals and Martin Shkreli’s former company Turing Pharmaceuticals. Both companies—and the latter's reviled former-CEO—have been summoned before the House and Senate to explain seemingly heartless price increases of life-saving medications.

Valeant has dramatically raised the prices of several drugs, including Isuprel, which is used in emergency situations to prevent fatally slow heart rates. The company raised the price from $50 to $2,700, leading some hospitals to put it under lock and key and pull it from medical carts that are used in life-threatening situations.

While Shkreli was CEO of Turing last year, the company raised the prices of an anti-parasitic medication called Daraprim from $13.50 a pill to $750. The medication is often prescribed to people with HIV/AIDS, pregnant women, and babies. With the price increase, some of those patients received $16,000 co-pays for a single prescription.

Turing and Valeant have largely been able to raise the prices because they are the sole producers of off-patent drugs that have relatively small patient populations—making the drugs less appealing for rival pharmaceutical companies to step in with competition. In the case of Daraprim, Turing was also able to stifle distribution, making it more difficult for generic producers to get enough of the drug to copy the recipe.

In a recent Congressional hearing, executives from both pharmaceutical companies reported making millions off the price increases. Subpoenaed documents revealed lavish parties and six-figure bonuses at Turing.

The new change by the FDA may thwart the next pharmaceutical company from making millions off of an off-patent drug. However, as Janet Woodcock, director of the Center for Drug Evaluation and Research with the Food and Drug Administration mentioned in the Congressional hearing, there was no generic applications to review for Daraprim at the time of the price increase.